<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076500</url>
  </required_header>
  <id_info>
    <org_study_id>NHS001688</org_study_id>
    <secondary_id>21-XTEAM-13</secondary_id>
    <nct_id>NCT05076500</nct_id>
  </id_info>
  <brief_title>Investigating the Tumour Immune Response of Radiotherapy</brief_title>
  <acronym>TIMM-RAD</acronym>
  <official_title>Investigating the Tumour Immune Response of Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manchester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate immune changes which occur before and following standard&#xD;
      radiotherapy in a range of tumour types. We will collect tissue and blood samples before and&#xD;
      after radiation treatment from participants across five cancer types: cervical, rectal, Head&#xD;
      and Neck cancer, nodal non-Hodgkin lymphoma and cutaneous lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this prospective, non-CTIMP, translational study is to assess the feasibility&#xD;
      of achieving paired biopsies for immune analysis in patients across five different cancer&#xD;
      types: cervical, rectal, Head and Neck cancer, nodal non-Hodgkin lymphoma and cutaneous&#xD;
      lymphoma.&#xD;
&#xD;
      All participants will have a minimum of 1 mandatory biopsy (during/post-radiotherapy&#xD;
      [irradiated site]) and the potential to have a pre-treatment biopsy if the archival biopsy&#xD;
      does not meet the suitability criteria.&#xD;
&#xD;
      Matched blood samples will be collected from participants at baseline,&#xD;
      during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is&#xD;
      taken, an additional end of treatment blood sample will be collected.&#xD;
&#xD;
      We aim to recruit 10 participants per study arm, with the option to increase numbers in study&#xD;
      arms that are recruiting well - a maximum of 100 patients in total will be recruited to the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of obtaining paired biopsy samples</measure>
    <time_frame>Within 6-7 weeks of starting radiotherapy</time_frame>
    <description>To assess the feasibility of obtaining tumour samples pre-radiotherapy (diagnostic or fresh) and a second biopsy during or immediately after radiotherapy, or a surgical sample, from patients undergoing standard of care RT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection of matched blood samples</measure>
    <time_frame>Within 6-7 weeks of starting radiotherapy</time_frame>
    <description>To obtain additional matched blood samples pre-radiotherapy, during or post-radiotherapy, and at the end of radiotherapy for assessment of immune status of peripheral blood in comparison to the intratumoural microenvironment.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Immunohistochemistry analysis of expression markers on tumour tissue</measure>
    <time_frame>Within 6-7 weeks of starting radiotherapy</time_frame>
    <description>Immunohistochemistry (IHC) analysis of expression markers on tumours pre-radiotherapy and during/post radiotherapy</description>
  </other_outcome>
  <other_outcome>
    <measure>RNA evaluation of immune signatures</measure>
    <time_frame>Within 6-7 weeks of starting radiotherapy</time_frame>
    <description>RNA evaluation of immune signatures in tumour tissue and blood pre-radiotherapy and during/post radiotherapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of peripheral blood mononuclear cells</measure>
    <time_frame>Within 6-7 weeks of starting radiotherapy</time_frame>
    <description>Assessment of changes in immune phenotypic markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of plasma proteins, cytokines and chemokines</measure>
    <time_frame>Within 6-7 weeks of starting radiotherapy</time_frame>
    <description>Analysis of plasma proteins, cytokines and chemokines as biomarkers of immune response</description>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cervical cancer</arm_group_label>
    <description>Cervical cancer patients receiving standard of care radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectal cancer</arm_group_label>
    <description>Rectal cancer patients receiving standard of care radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Head and neck cancer</arm_group_label>
    <description>Head and neck cancer patients receiving standard of care radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nodal non-Hodgkin lymphoma</arm_group_label>
    <description>Patients with nodal NHL receiving standard of care radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cutaneous lymphoma</arm_group_label>
    <description>Patients with cutaneous lymphoma receiving standard of care radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy and blood sample collection</intervention_name>
    <description>A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy [irradiated site]) will be collected from each participant.&#xD;
Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected.</description>
    <arm_group_label>Cervical cancer</arm_group_label>
    <arm_group_label>Head and neck cancer</arm_group_label>
    <arm_group_label>Rectal cancer</arm_group_label>
    <arm_group_label>cutaneous lymphoma</arm_group_label>
    <arm_group_label>nodal non-Hodgkin lymphoma</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Pre-treatment and during/post-treatment tumour tissue, and matched blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed cancer, Stage I-IV, in one of the following: Cervical,&#xD;
             rectal, nodal Non-Hodgkin lymphoma, cutaneous lymphoma, Head &amp; neck cancer&#xD;
&#xD;
          -  Diagnostic/pre-treatment biopsy confirmed suitable for translational research *&#xD;
&#xD;
          -  Performance status - ECOG 0-2 (Refer to appendix 1).&#xD;
&#xD;
          -  Age â‰¥ 18; no upper age limit.&#xD;
&#xD;
          -  Participant considered suitable for radiotherapy&#xD;
&#xD;
          -  Before participant registration, written informed consent must be given according to&#xD;
             GCP and national regulations.&#xD;
&#xD;
             *Pre-treatment biopsy must be from the gross tumour volume within the planned&#xD;
             radiation field and must also:&#xD;
&#xD;
          -  Have been formalin fixed for &gt;12h and &lt;72h&#xD;
&#xD;
          -  Have tumour tissue and morphology confirmed by H&amp;E staining&#xD;
&#xD;
          -  Contain sufficient tumour cells (approximately 100)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants deemed unsuitable for a biopsy (during or following radiotherapy) in the&#xD;
             opinion of the treating oncologist.&#xD;
&#xD;
          -  Participants who have received chemotherapy within 28 days of starting radiotherapy.&#xD;
&#xD;
          -  Participants with intercurrent or past history of hepatitis B, C or human&#xD;
             immunodeficiency virus infection if known. A negative test result for hepatitis B, C&#xD;
             and HIV infection is required prior to inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy M Illidge</last_name>
    <role>Study Chair</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Trigwell</last_name>
    <phone>01613066088</phone>
    <email>catherine.trigwell@manchester.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eleanor Cheadle</last_name>
    <phone>01613066027</phone>
    <email>eleanor.j.cheadle@manchester.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Trigwell</last_name>
      <phone>01613066088</phone>
      <email>catherine.trigwell@manchester.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manchester</investigator_affiliation>
    <investigator_full_name>Tim Illidge</investigator_full_name>
    <investigator_title>Professor of Targeted Therapy and Oncology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

